Synthesis, characterization and in vitro antimicrobial activity of cyclic imide: Isoindoline-1, 3-dione derivatives

Baluja Shipra 1,*, Chanda Sumitra 2 and Chavda Kalpen1

1Department of Chemistry, Saurashtra University, Rajkot-360005 (Gujarat), India.
2Department of Biosciences Saurashtra University, Rajkot-360005 (Gujarat), India.

Publication history: Received on 17 December 2019; revised on 11 January 2020; accepted on 13 January 2020

Abstract

A series of new cyclic imide: isoindoline-1, 3-dione derivatives were synthesized by condensation of 2-hydrazinyl-2-oxo-N-phenylacetamide and phthalic anhydride. The characterization of synthesized compounds was done by IR, 1H NMR, 13C NMR and mass spectroscopy. All these synthesized compounds were tested for in vitro antimicrobial activity against various bacterial and fungal strains in N, N-dimethyl formamide and Dimethyl sulfoxide. It is observed that almost all the compounds showed moderate antimicrobial activity and N, N-dimethyl formamide is better solvent than dimethyl sulfoxide.

Keywords: Cyclic imide; Isoindoline-1; 3-dione derivatives; N, N-dimethyl formamide; Dimethyl sulfoxide; Gram positive bacteria; Gram negative bacteria; Fungal strains

1. Introduction

Imides are diacyl derivatives of ammonia or primary amine. Among imides, cyclic imides and their N-derivatives contain bisamide linkages with a general structure of [-CO-N(R)-CO-] are the most important representatives of this class. These compounds are structurally related to acid anhydrides. The presence of oxygen and nitrogen atoms as co-ordination sites can attach these ligands with the biological system and cause various pharmacological effects [1, 2]. Due to hydrophobicity and neutral structures, these compounds can easily cross biological membranes in vivo [3-5]. In view of the favourable pharmacokinetic properties, derivatives of cyclic imides have been found to exhibit wide range of biological activities such as antibacterial [6-8], antifungal [9, 10], antiviral [11, 12], analgesic [13, 14], antiangiogenic [15, 16], anti-HIV [17-19], antimalarial [20], anticancer [21, 22], androgen receptor antagonistic [23], anti-inflammatory [24-26], anxiolytic [27, 28], anti-depressive [29], anticonvulsant [30, 31], hypolipidemic [32] and muscle-relaxant activities [33] etc.

A very important cyclic imide moiety; Isoindoline-1, 3-dione commonly known as phthalimide, is the key structural unit of a variety of biologically active molecules which are of pharmaceutical significance. Various drugs such as lenalidomide, pomalidomide, etc., contain isoindoline structure and these drugs have been used for the treatment of multiple myeloma [34, 35]. Various other isoindoline structure containing drugs are also known to be used for the treatment of certain types of diseases [36-38].

Thus, in present work, some new isoindoline-1, 3-dione derivatives have been synthesized. By some spectroscopic techniques such as IR, 1H NMR 13C NMR and mass, their structures were confirmed. The antimicrobial activity of the synthesized compounds was done against some pathogenic gram-positive and gram-negative bacteria and fungi in N,N-dimethyl formamide (DMF) and Dimethyl sulfoxide (DMSO).

*Corresponding author
E-mail address: shipra_baluja@rediffmail.com

Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0
2. Experimental

2.1. Material

Different substituted amines, hydrazine hydrates (99.9%), diethyl oxalate, phthalic anhydride, glacial acetic acid used for the synthesis, was supplied from Spectrochem Pvt. Ltd. (Mumbai, India) and was used without any treatment. The solvents methanol, 1,4-dioxane were used for synthesis and DMF, DMSO used for antimicrobial activity of synthesized derivatives were of AR grade supplied by Spectrochem Pvt. Ltd. (Mumbai, India). All the solvents used for activities were purified according to the standard procedure [39].

2.2. Synthesis

2.2.1. Synthesis of ethyl 2-oxo-2-[(phenylamino) acetate derivatives (Int-1)

A mixture of substituted amine (1.0 eq) and diethyl oxalate (1.05 eq) in 1,4-dioxane was refluxed for 5-6 hrs. The completion of reaction was confirmed by analytical thin layer chromatography (TLC) (Performed on aluminum coated plates Gel 60F254 (E. Merck)) using 7:3-Hexane: Ethyl acetate) as mobile phase. After completion of the reaction, reaction mass was cooled and was poured into crushed ice. The resulting solid was filtered, washed with hexane and dried under vacuum.

2.2.2. Synthesis of 2-hydrazinyl-2-oxo-N-phenylacetamide derivatives (Int-2)

A methanolic solution of ethyl 2-oxo-2-[(phenylamino) acetate (Int-1) (1.0 eq) and hydrazine hydrate (1.1 eq) was stirred at 0-5°C for 30 minutes. The progress of reaction was monitored by TLC using 5:5-Hexane: Ethyl acetate as mobile phase. The solid was filtered, washed with cold water and was dried.

2.2.3. Synthesis of isoindoline-1, 3-dione derivatives

Equimolar solution of 2-hydrazinyl-2-oxo-N-phenylacetamide (Int-2) and phthalic anhydride in glacial acetic acid was refluxed for 3-4 hrs. The progress of reaction was monitored by TLC using 6:4-Hexane: Ethyl acetate as mobile phase. After completion of reaction, the reaction mass was poured into crushed ice. The resulting solid was filtered, washed with water and was purified by silica-gel column chromatography. The pure fraction was collected in 60-40% Hexane: Ethyl acetate and solvent was evaporated under vacuum. All the synthesized compounds were recrystallized using THF. Figure 1 shows complete reaction scheme.

Overall, ten derivatives were synthesized, which are as follows:

**GMC-1**: N^1-(4-bromophenyl)-N^2-(1,3-dioxoisindolin-2-yl)oxalamide

**GMC-2**: N^1-(3-chloro-4-fluorophenyl)-N^2-(1,3-dioxoisindolin-2-yl)oxalamide

**GMC-3**: N^1-(4-chlorophenyl)-N^2-(1,3-dioxoisindolin-2-yl)oxalamide

**GMC-4**: N^1-(1,3-dioxoisindolin-2-yl)-N^2-(4-fluorophenyl)oxalamide

**GMC-5**: N^1-(1,3-dioxoisindolin-2-yl)-N^2-(4-methoxyphenyl)oxalamide

**GMC-6**: N^1-(1,3-dioxoisindolin-2-yl)-N^2-(p-tolyl)oxalamide

**GMC-7**: N^1-(3-chlorophenyl)-N^2-(1,3-dioxoisindolin-2-yl)oxalamide

**GMC-8**: N^1-(1,3-dioxoisindolin-2-yl)-N^2-(3-methoxyphenyl)oxalamide

**GMC-9**: N^1-(1,3-dioxoisindolin-2-yl)-N^2-(2-fluorophenyl)oxalamide

**GMC-10**: N^1-(3,4-dimethylphenyl)-N^2-(1,3-dioxoisindolin-2-yl)oxalamide.
Figure 1 Reaction Scheme

The characterization of these crystallized synthesized compounds was done by FT-IR, $^1$H NMR, $^{13}$C NMR and mass spectral data. IR spectra were recorded on Shimadzu furrier transport infrared spectrophotometer (Model No - IR affinity-1S), $^1$H NMR and $^{13}$C NMR spectra were taken on a Bruker AVANCE III (400 MHz). In all the cases, NMR spectra were obtained in deuterated dimethyl sulfoxide (DMSO-d$_6$) using TMS as an internal standard. The NMR signals are reported in δ ppm. The mass spectra were determined using direct inlet probe on a Shimadzu GC-MS (Model-QP-2010) mass spectrometer.

Table 1 shows the physical parameters of all the synthesized compounds.

The melting points of compounds were measured by differential scanning calorimeter (Model-Shimadzu-DSC-60) under nitrogen gas atmosphere.

Table 1 Physical parameters of Isoindoline-1, 3-dione derivatives

| Compound Code | Substitution R | Molecular Formula | Molecular Weight (gm/mol) | Yield (%) | $R_f$ value | Melting Points (°C) |
|---------------|----------------|-------------------|---------------------------|-----------|-------------|---------------------|
| GMC-1         | -4-Br          | C$_{16}$H$_{10}$BrN$_3$O$_4$ | 388.17 | 84 | 0.48 | 197.3 |
| GMC-2         | -3-Cl, 4-F     | C$_{16}$H$_{10}$ClF$_3$N$_3$O$_4$ | 361.71 | 75 | 0.49 | 174.6 |
| GMC-3         | -4-Cl          | C$_{16}$H$_{10}$ClN$_3$O$_4$ | 343.72 | 72 | 0.48 | 200.8 |
| GMC-4         | -4-F           | C$_{16}$H$_{10}$FN$_3$O$_4$ | 327.27 | 77 | 0.46 | 195.2 |
| GMC-5         | -4-OCH$_3$     | C$_{17}$H$_{13}$N$_2$O$_5$ | 339.30 | 82 | 0.39 | 252.4 |
| GMC-6         | -4-CH$_3$      | C$_{17}$H$_{13}$N$_2$O$_4$ | 323.30 | 81 | 0.47 | 235.9 |
| GMC-7         | -3-Cl          | C$_{16}$H$_{10}$ClN$_3$O$_4$ | 343.72 | 83 | 0.50 | 192.5 |
| GMC-8         | -3-OCH$_3$     | C$_{17}$H$_{13}$N$_2$O$_5$ | 339.30 | 79 | 0.45 | 186.7 |
| GMC-9         | -2-F           | C$_{16}$H$_{10}$FN$_3$O$_4$ | 327.27 | 73 | 0.50 | 188.6 |
| GMC-10        | -3,4-diCH$_3$  | C$_{18}$H$_{15}$N$_2$O$_4$ | 337.33 | 86 | 0.51 | 207.8 |

*0.6:0.4 - Hexane:Ethylacetate
2.3. Antimicrobial activity

2.3.1. Microorganisms tested

The selected microorganisms were obtained from National Chemical Laboratory (NCL), Pune, India. The microorganisms were maintained at 4°C. The Gram positive bacteria were Bacillus cereus ATCC11778 (BC), Bacillus subtilis ATCC6633 (BS), Staphylococcus aureus ATCC29737 (SA), Corynebacterium rubrum ATCC14898 (CR) and Gram negative bacteria were Escherichia coli NCIM2931 (EC), Pseudomonas aeruginosa ATCC27853 (PA), Klebsiella pneumoniae NCIM2719 (KP) and Salmonella typhimurium ATCC23564 (ST). The fungal strains were Candida glabrata NCIM3448 (CG), Candida albicans ATCC2091 (CA), Cryptococcus neoformans NCIM3542 (CN) and three clinical isolates of Candida species were C1, C2, C3.

The microorganisms studied are clinically important ones causing several infections and food spoilage. In vitro antimicrobial activity of all the synthesized compounds were studied against these pathogenic microbial strains by agar well diffusion method [40].

3. Results and discussion

The IR, 1H NMR, 13C NMR and mass spectra of a compound GMC-6 is shown in Figure 2, 3, 4 and 5 respectively.

The spectral data of all the compounds are given below.

3.1. Spectral data

3.1.1. GMC-1

IR (cm⁻¹): 3149.76 (Ar-C-H str.), 1685.79 (C=O str. amide), 1587.42 (N-H bend.), 1529.55 (N-H in plane amide), 1485.19 (Ar-C=C str.), 1155.36 (C-N str.), 817.82 (Ar-C-H oop. 1, 4-disubstituted ring), 704.02 (N-H oop. 2° amide), 610.23 (C-Br str.)

1H NMR (DMSO-d₆, 400 MHz) δ (ppm): 7.538-7.560 (2H, d, 8.80 Hz, Ar-CH), 7.616-7.636 (2H, d, 8.00 Hz, Ar-CH), 7.941-8.012 (4H, m, Ar-CH), 11.093 (1H, singlet, -NH-N), 11.812 (1H, singlet, -NH-Ar)

13C NMR (DMSO-d₆, 100 MHz) δ (ppm): 116.95, 122.36, 122.65, 123.88, 129.26, 131.48, 135.33, 136.54, 156.65, 159.11, 164.27. MS: (m/z) = 388.

Figure 2 IR spectrum of compound GMC-6
Figure 3 $^1$H NMR spectrum of compound GMC-6

Figure 4 $^{13}$C NMR spectrum of compound GMC-6
Figure 5 Mass spectrum of compound GMC-6

3.1.2. GMC-2

IR (cm⁻¹): 3149.76 (Ar-C=H str.), 1683.86(C=O str. amide), 1587.42 (N-H bend.), 1514.12 (N-H in plane amide), 1494.83 (Ar=C=C str.), 1157.29(C-N str), 1074.29 (C-F str.), 711.73 (C-Cl str.).

¹H NMR (DMSO-d₆) δ(ppm): 7.581 - 7.601 (2H, d, 8.00 Hz, Ar-CH), 7.826 - 8.014 (5H, m, Ar-CH), 11.026 (1H, singlet, -NH-N), 11.824 (1H, singlet, -NH-Ar).

¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm): 116.38, 116.59, 116.96, 122.39, 122.45, 122.74, 123.93, 129.26, 131.48, 131.60, 135.45, 136.56, 136.97, 157.02.

MS: (m/z) = 361.

3.1.3. GMC-3

IR (cm⁻¹): 3132.70 (Ar-C=H str.), 1658.78 (C=O str. amide), 1587.42 (N-H bend.), 1529.55 (N-H in plane amide), 1485.19 (Ar-C=C str.), 1056.99 (C-F str.), 817.82 (Ar-C=C-H oop. 1, 4-disubstituted ring), 711.73 (C-Cl str.).

¹H NMR (DMSO-d₆) δ(ppm): 7.378 - 7.400 (2H, d, 8.80 Hz, Ar-CH), 7.6654 - 7.685 (2H, d, 8.00 Hz, Ar-CH), 7.945 - 8.016 (4H, m, Ar-CH), 11.095 (1H, singlet, -NH-N), 11.816 (1H, singlet, -NH-Ar).

¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm): 121.04, 124.51, 127.88, 128.97, 130.11, 130.72, 135.33, 156.61, 159.09, 165.23.

MS: (m/z) = 343.

3.1.4. GMC-4

IR (cm⁻¹): 3120.82 (Ar-C=H str.), 1670.35(C=O str. amide), 1597.06(N-H bend.), 1539.20 (N-H in plane amide), 1490.97 (Ar=C=C str.), 1159.93(C-N str), 1082.07 (C-F str.), 810.10 (Ar-C=O oop. 1, 4-disubstituted ring), 707.88 (N-H oop. 2° amide).

¹H NMR (DMSO-d₆) δ(ppm): 7.018 - 7.040 (2H, d, 8.80 Hz, Ar-CH), 7.845-7.865 (2H, d, 8.00 Hz, Ar-CH), 7.931-8.145 (4H, m, Ar-CH), 11.093 (1H, singlet, -NH-N), 11.824 (1H, singlet, -NH-Ar).

¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm): 114.11, 121.09, 123.41, 130.13, 130.72, 134.31, 158.98, 156.63, 159.11, 164.27.

MS: (m/z) = 327.

3.1.5. GMC-5

IR (cm⁻¹): 3082.25 (Ar-C=H str.), 2964.59 (C-H alkane sym. Str. R-O-CH₃), 2837.29 (C-H alkane asym. Str. R-O-CH₃), 1678.07(C=O str. amide), 1595.13(N-H bend.), 1533.41 (N-H in plane amide), 1469.76 (Ar=C=C str.), 1265.30 (C-O-C str.), 1155.36(C-N str), 813.96 (Ar-C=O oop. 1, 4-disubstituted ring), 707.88 (N-H oop. 2° amide).

¹H NMR (DMSO-d₆) δ(ppm): 3.784 (3H, s, -OCH₃), 7.677-7.698 (2H, d, 8.40 Hz, Ar-CH), 7.467-7.488 (2H, d, 8.40 Hz, Ar-CH), 7.971-8.055 (4H, m, Ar-CH), 10.987 (1H, singlet, -NH-N), 11.847 (1H, singlet, -NH-Ar).

¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm): 55.85, 114.20, 122.50, 125.30, 130.51, 131.10, 131.52, 155.01, 160.80, 161.15, 164.37.

MS: (m/z) = 339.
3.1.6. GMC-6

**IR (cm⁻¹):** 3091.89 (Ar·C·H str.), 2982.61 (C·H alkane asym. Str. R-CH₃), 1664.57(C=O str. amide), 1597.06(N-H bend.), 1550.77 (N-H in plane amide), 1510.26 (Ar·C=C· str.), 1170.79(=C=N str.), 812.03 (Ar·C-H oop. 1, 4-disubstituted ring), 705.95 (N-H oop. 2° amide). **¹H NMR (DMSO-d₆) δ(ppm):**2.294 (3H, s, -CH₃), 7.187-7.208 (2H, d, 8.40 Hz, Ar·CH·), 7.707-7.728 (2H, d, 8.40 Hz, Ar·CH), 7.967-8.045 (4H, m, Ar·CH), 10.908 (1H, singlet, -NH·N), 11.782 (1H, singlet, -NH·Ar). ¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm):20.52, 120.77, 124.02, 129.15, 134.19, 134.15, 134.60, 135.57, 156.39, 159.46, 164.42. **MS: (m/z) =323.**

3.1.7. GMC-7

**IR (cm⁻¹):** 3084.18 (Ar·C-H str.), 1676.14 (C=O str. amide), 1591.27 (N-H bend.), 1502.55 (N-H in plane amide), 1413.82 (Ar·C=C· str.), 727.16 (Ar·C-H oop. 1, 3-disubstituted ring), 704.02 (C·C str.). **¹H NMR (DMSO-d₆) δ(ppm):**7.448 (1H, m, Ar·CH), 7.860-7.897 (2H, m, Ar·CH), 7.913 (1H, s, Ar·CH), 7.945-8.016 (4H, m, Ar·CH),10.979 (1H, singlet, -NH·N), 11.797 (1H, singlet, -NH·Ar). ¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm):119.97, 120.88, 124.61, 124.75, 128.63, 131.41, 131.63, 132.77,137.63, 156.41, 159.51, 164.47. **MS: (m/z) =343.**

3.1.8. GMC-8

**IR (cm⁻¹):** 3080.32 (Ar·C-H str.), 2974.23 (C·H alkane asym. Str. R-O-CH₃), 2860.43 (C·H alkane sym. Str. R-O-CH₃), 1685.79(C=O str. amide), 1597.06(N-H bend.), 1554.63 (N-H in plane amide), 1483.26 (Ar·C=C· str.), 1278.81 (C=O·C str.), 1163.08(=C=N str.), 742.59 (Ar·C-H oop. 1, 3-disubstituted ring), 707.88 (N-H oop. 2° amide). **¹H NMR (DMSO-d₆) δ(ppm):**3.823 (3H, singlet, -OCH₃), 7.345 (1H, m, Ar·CH), 7.671-7.676 (2H, m, Ar·CH), 7.875 (1H, s, Ar·CH), 7.945-8.016 (4H, m, Ar·CH),10.918 (1H, singlet, -NH·N), 11.797 (1H, singlet, -NH·Ar). ¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm):55.97, 105.45, 108.42, 114.11, 124.41, 128.31, 131.43, 131.73, 137.67, 156.49, 159.01, 159.54, 164.51. **MS: (m/z) =339.**

3.1.9. GMC-9

**IR (cm⁻¹):** 3136.25 (Ar·C-H str.),1680.00(C=O str. amide), 1597.06 (N-H bend.), 1550.77 (N-H in plane amide), 1483.26 (Ar·C=C· str.), 1172.72(=C=N str.), 1082.07 (C·F str.), 759.95 (Ar·C-H oop. 1, 2-disubstituted ring), 702.09 (N-H oop. 2° amide). **¹H NMR (DMSO-d₆) δ(ppm):**7.711-7.851 (3H, m, Ar·CH), 7.875-7.911 (1H, m, Ar·CH), 7.945-8.016 (4H, m, Ar·CH),10.918 (1H, singlet, -NH·N), 11.797 (1H, singlet, -NH·Ar). ¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm):115.53, 123.93, 124.57, 124.63, 124.74, 125.17, 131.42, 131.71, 154.49, 159.17, 159.83, 164.91. **MS: (m/z) =327.**

3.1.10. GMC-10

**IR (cm⁻¹):** 3091.89 (Ar·C-H str.), 2972.31 (C·H alkane asym. Str. R-CH₃), 1658.78(C=O str. amide), 1593.20(N-H bend.), 1498.69 (N-H in plane amide), 1471.67 (Ar·C=C· str.), 1118.71(=C=N str.), 704.02 (N-H oop. 2° amide). **¹H NMR (DMSO-d₆) δ(ppm):**1.986 (3H, s, -CH₃), 2.902 (3H, s, -CH₃), 6.882-6.901 (1H, d, Ar·CH), 7.064-7.087 (2H, m, Ar·CH), 7.945-8.016 (4H, m, Ar·CH),10.918 (1H, singlet, -NH·N), 11.797 (1H, singlet, -NH·Ar). ¹³C NMR (DMSO-d₆, 100 MHz) δ(ppm):19.45, 20.37, 118.55, 121.13, 124.61, 128.50, 131.39, 131.67, 133.21, 135.44, 136.22, 159.11, 159.71, 164.79. **MS: (m/z) =337.**

3.2. Antimicrobial activity

Figure 6 represents the zone of inhibition of compounds against Gram positive bacteria. It is observed that in DMF, out of four Gram positive bacterial strains selected for the study, only BC and BS could be affected by the synthesized compounds. Against BC, GMC-3 had no effect at all whereas GMC-4, GMC-5, GMC-6, GMC-7 and GMC-8 exhibited almost equal zone of inhibition. Minimum inhibition was exhibited by GMC-1 and GMC-2. For BS, GMC-1, GMC-8 and GMC-9 showed maximum inhibition whereas GMC-6 had no effect at all. Other compounds also exhibited significant inhibition. In DMSO, not a single synthesized compound could inhibit BC, SA and CR. Against BS, only GMC-1, GMC-8 and GMC-9 exhibited and maximum inhibition was by GMC-9. Thus, zone on inhibition depends on solvent, bacterial strain as well as on structure of compounds. As evident from Figure 6 that for these synthesized compounds, DMF is better solvent than DMSO.

Table 1 shows that central moeity for all the compounds is same but substitutions are different which gives different zone of inhibition. Thus, in DMF against BC, 4-chloro substitution present in GMC-3 is not effective at all. However, when chloro group is present at 3° position, it exhibited maximum inhibition. This suggests that position of group also play an important role in inhibition. Other substitutions had significant effect on BC. For BS, 4-methyl group had no effect. 4-bromo (as in GMC-1), 3-methoxy (as in GMC-8) and 2-fluoro (as in GMC-1) had maximum effect. GMC-5 also contains methoxy group but at 4° position but inhibition is less by GMC-5, which again prove the effect of position of group on inhibition.
In DMSO, against BS, only 3-methoxy (as in GMC-8), 2-fluoro (as in GMC-9) and 3, 4-dimethyl (as in GMC-10) groups were effective and 2-fluoro substitution had maximum inhibition.

Thus, in DMF, both SA and CR gram positive bacteria are resistant and BC and BS are susceptible. In DMSO, BC, SA and CR are resistant and only BS is susceptible.

**Figure 6** The zone of inhibition of isoindolinone-1,3-dione derivatives against Gram positive bacteria in DMF and DMSO

GMC-1, (■); GMC-2, (■); GMC-3, (■); GMC-4, (■); GMC-5, (■); GMC-6, (■); GMC-7, (■); GMC-8, (■); GMC-9, (■); GMC-10, (■)

Figure 7 shows the zone of inhibition of compounds against gram negative bacteria in DMF and DMSO. In DMF, against EC, all the compounds were effective except GMC-10. Thus, 3, 4-di-methyl group is not effective at all. The inhibition exhibited by GMC-2, GMC-7, and GMC-8 are equal and maximum. That is, 3-chloro, 4-fluoro (as in GMC-2), 3-chloro (as in GMC-7), and 3-methoxy (as in GMC-8) groups are most effective. Other groups could also inhibit this strain to some extent. For KP, except GMC-4, GMC-8 and GMC-10, all the compounds exhibited inhibition and almost to the same extent. Thus, for KP, 4-fluoro, 3-methoxy and 3,4-dimethyl groups are not effective at all. For PA, except GMC-3 and GMC-4, all the compounds exhibited inhibition and inhibition is almost same and maximum for GMC-1, GMC-2, GMC-5, GMC-7 and GMC-8. So, 4-chloro and 4-fluoro groups are not effective for PA. None of the compound could inhibit ST. Thus, in DMF, ST is the most resistant bacteria.

In DMSO, only GMC-9 containing 2-fluoro group exhibited inhibition against EC. Other compounds had no effect. For other three strains i.e., KP, PA and ST, none of the compound exhibited inhibition.
Figure 7 The zone of inhibition of isoindolinone-1, 3-dione derivatives against Gram negative bacteria in DMF and DMSO

GMC-1, (■); GMC-2, (▲); GMC-3, (■); GMC-4, (■); GMC-5, (▲); GMC-6, (■);
GMC-7, (■); GMC-8, (■); GMC-9, (■); GMC-10, (■)

Figure 8 shows zone of inhibition of compounds against fungal strains and clinical isolates. In DMF, all the compounds exhibited inhibition against all the three fungal strains as well as clinical isolates. Thus, all the substitutions are effective in inhibiting the selected fungal strains. For CA, 3-chloro group present in GMC-7 is most effective. For CG, both 3-chloro group (present in GMC-7) as well as 3-methoxy group (present in GMC-8) are equally effective whereas against CN, various substitution groups are effective. The 3-chloro,4-fluoro (in GMC-2), 4-fluoro (in GMC-4), 4-methoxy (in GMC-5), 4-methyl (in GMC-6), 4-chloro (in GMC-7) and 3, 4-dimethyl (in GMC-10) groups are equally effective.

In DMSO, all the compounds exhibited inhibition against C1 and C2. For C2, except GMC-10, all showed inhibition. However, against CA, only GMC-1 containing 4-bromo and GMC-6 containing 4-methyl groups showed inhibition. Other compounds had no effect at all. For CG, none of the compound was effective at all. Against CN, all the compounds are found to be effective and substitution groups 4-fluoro and 3,4-dimethoxy present in GMC-9 and GMC-10 are most effective. Thus, CG is most resistant whereas CN is most susceptible fungal strain.
Figure 8 The zone of inhibition of isoindolinone-1,3-dione derivatives against fungal strains and clinical isolates in DMF and DMSO

Against all the clinical isolates, all the studied compound had inhibition which varies depending upon the type of substitution group and solvent. Figure 8 shows that in both the solvents, compounds had significant inhibition against clinical isolates.

In DMF, against clinical isolate C1, GMC-7 (containing 3-chloro group) is more effective against C1. GMC-9 (containing 2-flouro) and GMC-10 (containing 3, 4 dimethyl groups) compounds are found to be less effective than others. Rest of the compounds possess moderate inhibition. For C2, GMC-1, GMC-5 and GMC-6 showed maximum inhibition. That is, 4-bromo, 4-methoxy and 4-methyl groups are equally effective. GMC-9 (2-F) and GMC-4 (4-F) shows minimum inhibition. Other compounds also affected C2. For C3, GMC-9 containing 2-fluoro group is most effective in DMF. Other substitution groups also exhibited significant effect.
In DMSO, against C1, GMC-9 (containing 2-flouro) and GMC-10 (containing 3, 4 dimethyl groups) compounds are found to be most effective than others. Rest of the compounds possess significant inhibition. For C2, in DMSO, GMC-5 (containing 4-OCH₃ group) and GMC-7 (containing 3-chloro group) exhibited maximum inhibition. GMC-3 (containing 4-chloro group) and GMC-8 (containing 3-OCH₃ group) showed minimum inhibition. Rest of the compounds could also inhibit to some extent. Against GMC-1 and GMC-6 containing 4-bromo and 4-methyl groups are very effective as compared to other groups. Minimum inhibition is exhibited by 3-chloro group present in GMC-3.

4. Conclusion

For all the synthesized compounds against studied bacterial and fungal strains, DMF is found to be better solvent. In both DMF and DMSO, the Gram positive bacteria; SA and CR are most resistant bacteria. In case of Gram negative bacteria, in DMF, ST is most resistant bacteria. In DMSO, all the selected four strains i.e., EC, KP, PA and ST are resistant as only one compound showed inhibition against EC. It is observed against selected Gram positive and Gram negative bacterial strains, mostly compounds containing halogen and methoxy groups are more effective. Further, position of substitution group affects inhibition. The synthesized compounds are found to be more effective against selected fungal strains and clinical isolates. Thus, novel compounds can be synthesized with halogen and methoxy groups which will inhibit these strains.

Compliance with ethical standards

Acknowledgments

Authors are thankful to Head of Chemistry department and Head of Bioscience Department for providing necessary facilities to carry out this work.

Disclosure of conflict of interest

There is no conflict of interest.

References

[1] Sultana K, Khan N and Shahid K. (2014). Synthesis characterization and in vitro antibacterial evaluation of Sn, Sb, and Zn coordination complexes of 2-(2-methoxyphenyl)-1H-isoindole-1, 3 (2h)-dione. Int. J. Pharm. Sci. Rev. Res., 28, 1-5.

[2] Alaa A, Angeli A, El-Azab A, El-Enin M and Supuran C. (2017). Synthesis and biological evaluation of cyclic imides incorporating benzenesulfonamide moieties as carbonic anhydrase I, II, IV and IX inhibitors, Bioorg. Med. Chem. 25, 1666-1671.

[3] El-Kabbani O, Darmanin C, Schneider T, Hazemann I, Ruiz F, Oka M, Joachimiak A, Schulze-Briese C, Tomizaki T, Mitschler A and Podjarny A. (2004). Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors, Proteins: Struc. Func. Bioinform., 55, 805-813.

[4] Kushwaha N and Kaushik D. (2016). Recent advances and future prospects of phthalimide derivatives, J. App. Pharma. Sci.,6, 159-71.

[5] Asif M. (2019). A Review on Biological and Chemical Potential of Phthalimide and Maleimide Derivatives, Acta Sci. Pharm. Sci., 3, 51-67.

[6] Patil M and Rajput S. (2016). Synthesis and Antimicrobial evaluation of some novel Diazot derivative of Cyclic Imides using Diazotization coupling reaction, Chem. Sci. Rev. Lett., 517, 46-52.

[7] Ahmed W, Mahmood A and Al-Bayati R. (2018). Synthesis and Evaluation of Antimicrobial Activity of New Imides and Schiff Bases Derived from Ethyl-4-Amino Benzoate, Orient. J. Chem., 34, 2477-2486.

[8] Kumari S, Gupta V, Singh S and Gupta V. (2019). Synthesis, Characterization and Antimicrobial Activities of five and six member Cyclic Imides Derivatives, Res. J. Sci. Tech., 11, 82-86.

[9] Stiz D, Corrêa R, Dauria F, Simonetti G and Cechinel-Filho V. (2016). Synthesis of cyclic imides (Methylphthalimides, carboxylic acid phthalimides and itaconimides) and evaluation of their antifungal potential, Med. Chem., 12, 647-654.

56
[10] Chaudhari P and Rajput S. (2016). One pot synthesis and antimicrobial evaluation of some novel bis-chalcones and pyrazoles from cyclic imides under microwave irradiation, World J. Pharm. Res., 5, 1301-1313.

[11] Torres E, Duque M, Camps P, Naensens L, Calvet T, Font-Bardia M and Vázquez S. (2010). Polycyclic N-Benzamido Imides with Potent Activity against Vaccinia Virus, Chem. Med. Chem., 5, 2072-2078.

[12] Dhivare S and Rajput S. (2015). Synthesis and antimicrobial activity of five membered cyclic imide derivatives of mono, di and tri substituted aromatic amines and napthyl amine, World J. Pharm. Sci., 4,1650-1658.

[13] Andricopulo A, Muller L, CechinelFilho V, Cani G, Roos J, Correa R, Santos A, Nunes R and Yunes R. (2000) Analgesic activity of cyclic imides: 1, 8-napthalenediimide and 1, 4, 5, 8-napthalenediimide derivatives, Farmaco, 55, 319-321.

[14] Alanazi A, El-Azab A, Al-Suwaidan I, ElTahir K, Asiri Y, Abdel-Aziz N and Alaa A. (2015). Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities. European journal of medicinal chemistry, 92, 115-123.

[15] Muller G, Konnecke W, Smith A and Khetani V. (1999). A concise two-step synthesis of thalidomide, Org. Process Res. Dev., 3, 139-140.

[16] W Figg, Eger K, Teubert U, Weiss M, Guetschow M, Hecker T and Hauschildt S. (2008). Analogs of thalidomide as potential angiogenesis inhibitors, National Institutes of Health (NIH), U.S. Patent, 7, 320,991.

[17] Makonkawkeyoon S, Limson-Pobre R, A Moreira, V Schaaf and G Kaplan. (1993). Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci., 90, 5974-5978.

[18] Figg W, Raje S, Bauer K, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J and Reed E. (1999). Pharmaco kinetics of thalidomide in an elderly prostate cancer population, J. Pharm. Sci., 88, 121-125.

[19] Sperka T, Pitlik J, Bagossi P and Tozser J. (2005) Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett., 15, 3086-3090.

[20] Ebrahim I, Jarrahpour A, Heidari N, Sinou V, Latour C, Brunel J, Zolghadr A and Turos E. (2016) Synthesis and antimalarial activity of new nanocopolymer β-lactams and molecular docking study of their monomers, Med. Chem. Res., 25(2), 247-262.

[21] Sondhi S, Rani R, Roy P, Agrawal S and Saxena A. (2009). Microwave-assisted synthesis of N-substituted cyclic imides and their evaluation for anticancer and anti-inflammatory activities, Bioorg. Med. Chem. Lett., 19, 1534-1538.

[22] Alaa A, El-Azab A, Ghia ty A, Gratteri P, Supuran C and Nocentini A. (2019). 4-Substituted benzenesulfonamides featuring cyclic imides moieties exhibit potent and isoform-selective carbonic anhydrase II/IX inhibition, Bioorg.Chem.,83, 198-204.

[23] Patil M and Rajput S. (2014). Succinimides: Synthesis, reaction and biological activity. Int. J. Pharm. Pharm. Sci., 6, 8-14.

[24] Campos F, Correa R, de Souza M, Yunes R, Nunes R and Cechinel-Filho V. (2002). Studies on new cyclic imides obtained from aminophenazone with analgesic properties, Arzneimittel forsch., 52, 455-461.

[25] Machado M, Lima L, Araujo-Jr J, Fragas C, Koatz V and Barreiro E. (2005). Design, synthesis and anti-inflammatory activity of novel phthalimide derivatives, structurally related to thalidomide, Bioorg. Med. Chem. Lett., 15, 1169-1172.

[26] Zimmermann-Franco D, Esteves B, Lacerda L, I de Oliveira Souza, J dos Santos, N Pinto, E Scio, A da Silva and G Macedo. (2018). In vitro and in vivo anti-inflammatory properties of imine resveratrol analogues, Bioorg. Med. Chem., 26, 4988-4906.

[27] Hassanzadeh F, Rabbani M, Fasihi A, Hakimelahi G and Mohajeri M. (2008). Synthesis of phthalimide derivatives and evaluation of their antiplatelet activity, Res. Pharm. Sci., 2, 35-41.

[28] Gajare S and Mahajan S. (2012). QSAR studies of phthalimide derivatives for their potent antiplatelet activity. Int. J. Cur. Res. Rev., 4, 151-156.

[29] De Munck L, Vila C and Pedro J. (2018). Catalytic Asymmetric Reactions Involving the Seven-Membered Cyclic Imine Moieties Present in Dibenzo [b, f] [1, 4] oxazepines, Eur. J. Org. Chem., 2, 140-146.

[30] Stratford E and Curley Jr R. (1983). Synthesis of aminomethyl-substituted cyclic imide derivatives for evaluation as anticonvulsants, J. Med.Chem., 26, 1463-1469.
[31] Kathuria V and Pathak D. (2012). Synthesis and anticonvulsant activity of some N-substituted-phthalimide analogs. The Pharma. Innov., 1, 55-59.

[32] Sena V, Srivastava R, Silva R and Lima V. (2003). Synthesis and hypolipidemic activity of N-substituted phthalimides. Part V, Farmaco., 58, 1283-1288.

[33] Musso D, Cochran F, Kelley J, McLean E, Selph J, Rigdon G, Orr G, Davis R, Cooper B, Styles V, Thompson J and Indanylidenes. (2003). Design and synthesis of (E)-2-(4, 6-difluoro-1-indanylidene) acetamide, a potent, centrally acting muscle relaxant with anti-inflammatory and analgesic activity. J. Med. Chem., 46, 399-408.

[34] Anderson A, Kiernan M and Ho P. (2019). Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma, Clin. Lymphoma Myeloma Leuk., 19, 169-171.

[35] Eleutherakis-Papaioannou, M Gavriatopoulou, I Ntanasis-Stathopoulos, E Kastritis, ETerpos and M Dimopoulos. (2019). Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma, Expert Rev. Anticancer Ther., 19, 1-8.

[36] Metyas S, Tomassian C, Messiah R, Gettas T, Chen C and Quismorio A. (2019). Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis, Curr. Rheumatol. Rev., 15, 234-237.

[37] Nagasawa H, Elberling J and Shiota F. (1980). Latentiated forms of the transport-inhibitory α-amino acid Adamantanine. J. Pharm. Sci., 69, 1022-1025.

[38] Hall I, Wong O and Scovill J. (1995). The cytotoxicity of N-pyridinyl and N-quinolinyl substituted derivatives of phthalimide and succinimide, Biomed. Pharm., 49, 251-258.

[39] Riddick J, Bunger W and Sakano T. (1986). Organic solvents: Physical properties and methods of purification, Fourth Edition., Techniques of Chemistry, II, A Wiley-Inter science Publication, John Wiley, New York.

[40] Parekh J, Inamdar P, Nair R, Baluja R and Chanda S. (2005). Synthesis and antibacterial activity of some Schiff bases derived from 4-aminobenzoic acid, J. Serb. Chem. Soc., 70, 1155-1158.

How to cite this article
Baluja S, Chanda S and Chavda K. (2020). Synthesis, characterization and in vitro antimicrobial activity of cyclic imide: Isoindoline-1, 3-dione derivatives. GSC Biological and Pharmaceutical Sciences, 10(1), 46-58.